AUNP-12 TFA(Synonyms: NP-12 TFA)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

AUNP-12 TFA (Synonyms: NP-12 TFA) 纯度: ≥96.0%

AUNP-12 (NP-12) TFA 是 PD-1 信号通路的一种多肽拮抗剂,在抑制淋巴细胞增殖和效应功能方面对 PD-L1 和 PD-L2 具有等效的拮抗作用。AUNP-12 TFA 具有免疫激活作用、良好的抗肿瘤活性,具有更好的研究免疫相关不良事件 (irAEs) 的潜力。

AUNP-12 TFA(Synonyms: NP-12 TFA)

AUNP-12 TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ¥1300 In-stock
5 mg ¥3400 In-stock
10 mg ¥5600 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

AUNP-12 TFA 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1].

IC50 & Target

PD-1 signaling pathway[1]

体外研究
(In Vitro)

NP-12 TFA displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions [1].
NP-12 TFA rescues the proliferation in the mouse splenocyte assay system with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively [1].
NP-12 TFA is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively [1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

3375.57

Formula

C5H17TFIN2O2S2Si

Sequence Shortening

H-SNTSESFKF(H-SNTSESF)RVTQLAPKAQIKE-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献
  • [1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务